Akebia Therapeutics (AKBA) Share-based Compensation Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Share-based Compensation Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 10.35% |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 40.57% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 67.91% |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 12.76% |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 20.51% |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 17.07% |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 18.39% |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 53.43% |
| 10 | Akebia Therapeutics | 245.66 Mn | 83.06 Mn | 41.25 Mn | 13.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.80% |
| Dec 31, 2025 | 1.70% |
| Sep 30, 2025 | -1.35% |
| Jun 30, 2025 | -27.13% |
| Mar 31, 2025 | -21.59% |
| Dec 31, 2024 | -28.47% |
| Sep 30, 2024 | -33.48% |
| Jun 30, 2024 | -31.74% |
| Mar 31, 2024 | -26.70% |
| Dec 31, 2023 | -37.11% |
| Sep 30, 2023 | -34.84% |
| Jun 30, 2023 | -20.19% |
| Mar 31, 2023 | -20.30% |
| Dec 31, 2022 | -14.90% |
| Sep 30, 2022 | 8.69% |
| Jun 30, 2022 | 44.68% |
| Mar 31, 2022 | 29.39% |
| Dec 31, 2021 | -27.29% |
| Sep 30, 2021 | 35.42% |
| Jun 30, 2021 | 37.72% |